A randomized, controlled, single-blind trial of leflunomide in the treatment of rheumatoid arthritis

Abstract

The efficacy and safety of leflunomide (LEF) in the treatment of rheumatoid arthritis (RA) were evaluated and the comparison with methotrexate’s (MTX’s) was performed in a 12-week, single-blind, randomized, parallel trial for treating 81 patients with RA. There were 56 cases in LEF group and 25 cases in MTX group. The dose of LEF was 20 mg per day and MTX 15 mg per week. All patients took oxaproxin simultaneously at the 4th to 6th week after the trail. The results showed that the general effective rate and notable effective rate were 94. 64 % and 73. 21 % in LEF group, 72 % and 44 % in MTX group, respectively, with the differences being statistically significant between the two groups (P<0. 05). LEF and oxaprozin could obviously improve the symptoms, signs and joint functions. The incidence of side reactions was lower in LEF group (17. 86 %) than in MTX group (40. 00 %,P<0. 05). LEF had a good therapeutic effect for RA, especially for refractory RA and had slight side reactions, and could be regarded as a superior immunosuppressive agent used in the treatment of RA and other connective tissue diseases.

Keywords

lefunomide / methotrexate / rheumatoid arthritis

References

[1] Herrman M, Frangou C G, Kirschbaum Bet al. Cell cycle control of the de novo pyrimidine synthesis inhibitor leflunomide through the P53 and p21WAF-l pathways. ACR Poster Session, 1997, abstract: 875

[2] AmettF C, EdworthyS, BlockD A, et al.. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rherm, 1988, 31(3): 315-315

[3] BarlettR R. Leflunomide, an immunorestoring drug for the therapy autoimmune disorders, especially rheumatoid. Curr Opin Rheu, 1997, 9: 410-410